21 Best Healthcare Companies to Invest In
These companies largely earn their competitive advantage from intangible assets and their stocks are great choices for an investor’s watchlist.
The strongest long-term opportunity for healthcare companies primarily falls in three industries: drug manufacturing, medical devices, and diagnostics and research.
And nearly all of the best healthcare companies to invest in—20 of the 21 companies on our list—have intangible assets that provide a wide moat against competitors. This intangible-asset advantage is often derived from either patents or proprietary technology.
Patents are temporary government licenses that exclude competition from copying an invention. For example, in pharmaceutical companies, patents are necessary owing to the ease with which some drugs can be replicated. Similarly, patents are vital in the medical devices industry to protect companies’ product designs.
Proprietary technology encompasses more complex processes and tools than a company’s patents might cover—many companies keep their intellectual property as a trade secret rather than provide a public description in a patent application. In general, the more sophisticated and customized a product or service becomes, the more that proprietary technology plays a role in driving competitive advantage. In healthcare, this is seen in biopharma, medical devices, and contract research organizations.
Here, we highlight the 21 healthcare companies that made our list of the best companies to own in 2022. These companies earned their spot on the list by both having carved-out wide moats and having made smart capital decisions.
This is the second major sector from that list that we’re deconstructing; previously we touched on the financial-services industry.
Because this list is built for the long term, rather than to identify presently undervalued companies, it may not be the right time to buy all these names. Rather, we believe these healthcare companies are strong choices for an investor’s watchlist.
You should consider buying only when they’re trading below our price/fair value estimate, which assesses whether a stock’s price is high or low compared with its fundamental value.
All the drug manufacturers on the best companies list, both general and specialty, gain an edge from their intangible assets.
Pfizer (PFE) is a prominent member of the group. “Pfizer’s patent-protected drugs carry strong pricing power that enables the firm to generate returns on invested capital in excess of its cost of capital,” writes Morningstar Research Services’ sector director Damien Conover, CFA. “The patents give the company time to develop the next generation of drugs before generic competition arises.”
Johnson & Johnson (JNJ), the world’s largest and most diverse healthcare firm, with a market cap of $489 billion, also thrives in this area. Conover notes that Johnson & Johnson’s wide moat is “supported by intellectual property in the drug group…and strong brand power from the consumer group. Despite carrying some lower-margin divisions, J&J maintains strong pricing power and has posted gross margins above 70% during the past four years, validating its strong competitive position.”
Eight of the 20 companies with a moat driven by intangible assets have an additional moat source, either a cost advantage or high switching costs.
Of the six qualifying companies in either the diagnostic and research or medical devices industries, all have an advantage from intangible assets and five further benefit from switching costs. (Medtronic (MDT) is the lone company among them that doesn’t have a switching cost advantage.)
With a market cap of $216 billion, Thermo Fisher Scientific (TMO) is the largest of the diagnostics and research companies on the list. Thermo Fisher sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents.
Like key competitors Agilent (A) and Waters (WAT), Thermo Fisher’s analytical instrument business benefits intangible assets and switching costs, says regional director of Equity Research of Morningstar Holland Alex Morozov, CFA. “The intangible asset is the firm’s differentiated technology and its leadership positions within tools such as mass spectrometry, chromatography, microscopy and others…The business is also rather sticky, particularly within the biopharma end market, where the regulatory process assures high switching costs. Production methods have to stay uniform throughout the life cycle of a drug, which often extends beyond the life cycle of a typical mass spectrometer.”
Medical devices, for their part, have high switching costs because surgeons develop expertise in using a differentiated set of tools and device systems have component parts that are designed to work together.
“The highest switching costs in medical devices is in orthopedics where all the device makers have their own differentiated implants and the tools to install the implants,” says Morningstar Research Services senior analyst Debbie S. Wang.
“It takes years for the orthopedic surgeons to become practiced enough on one vendor’s tools and implants to deliver optimal patient outcomes, and after they have mastered them, they are reluctant to switch to another vendor where they’d have to re-learn some of it,” Wang explains. “For this reason, the switching costs are the highest for companies like Zimmer Biomet (ZBH) and Stryker (SYK).”
Novo Nordisk is the leading provider of diabetes-care products in the world, holding 50% of world market share. The company has two moat sources: intangible assets and cost advantage. As for the latter, Morningstar Research Services sector strategist Karen Andersen, CFA, notes: “Efficient manufacturing techniques and economies of scale allow Novo's insulin business to provide strong global profitability.”
Veeva is a leading supplier of software solutions for the life sciences industry. It is the only company on the list without an intangible asset moat source. However, the advantage it gains from switching costs is enough to provide a wide moat against competition. “Once integrated into a company’s operating activities, the direct time and expense of switching to a competing software solution is high and comes with substantial operating risks,” says Morningstar Research Services analyst Dylan Finley, CFA.
Benjamin Slupecki does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.